|
EWSR1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.58660004526234E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.16260000024593E-07 |
| Normal-vs-Stage2 |
3.775600E-04 |
| Normal-vs-Stage3 |
1.76169999699383E-08 |
| Normal-vs-Stage4 |
5.0274229224101E-12 |
| Stage1-vs-Stage2 |
5.535600E-01 |
| Stage1-vs-Stage3 |
1.217560E-01 |
| Stage1-vs-Stage4 |
1.350540E-04 |
| Stage2-vs-Stage3 |
6.369800E-01 |
| Stage2-vs-Stage4 |
5.195600E-02 |
| Stage3-vs-Stage4 |
3.383800E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.80929998445146E-09 |
| Normal-vs-AfricanAmerican |
4.082100E-03 |
| Normal-vs-Asian |
5.399000E-03 |
| Caucasian-vs-AfricanAmerican |
5.560800E-01 |
| Caucasian-vs-Asian |
1.993600E-01 |
| AfricanAmerican-vs-Asian |
7.574800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.26540000039621E-07 |
| Normal-vs-Female |
4.34119995507132E-09 |
| Male-vs-Female |
9.678400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.13879999985578E-07 |
| Normal-vs-Age(41-60Yrs) |
3.3778999997125E-07 |
| Normal-vs-Age(61-80Yrs) |
4.19909662596751E-11 |
| Normal-vs-Age(81-100Yrs) |
1.060590E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.928800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.758400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.029000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.820190E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.509600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.907700E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.564400E-03 |
| Classical-VS-Follicular |
3.327500E-02 |
| Classical-VS-Other |
8.234400E-02 |
| Classical-VS-Normal |
1.73173999999943E-05 |
| Tall-VS-Follicular |
3.371800E-01 |
| Tall-VS-Other |
8.395400E-01 |
| Tall-VS-Normal |
4.08730005396762E-09 |
| Follicular-VS-Other |
6.064200E-01 |
| Follicular-VS-Normal |
4.14660000003231E-07 |
| Other-VS-Normal |
3.382600E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.6256999997627E-08 |
| Normal-vs-N1 |
6.98370000051796E-07 |
| N0-vs-N1 |
2.789800E-01 |
|
|
